Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy. In two-thirds of patients, it is preceded by an upper respiratory or gastrointestinal tract infection. Temporally associated cases of GBS following COVID-19 vaccination have been described with different COVID-19 vaccines. In this study, we report three cases of GBS patients following COVID-19 vaccine. Two of the studied patients received the Sinopharm vaccine and one patient received the AstraZeneca vaccine. All patients were diagnosed with acute motor axonal neuropathy (AMAN) type of GBS, on nerve conduction studies. All three patients responded well to treatment with intravenous immunoglobulin (IVIg). The association between COVID-19 vaccination and GBS is not well understood and more studies are needed to establish whether it is merely an association or a causal relationship.

We report two cases of previously healthy young men with COVID-19 infection who developed acute ischemic stroke due to large vessel occlusion followed by secondary events concerning for a further thromboembolic event. We hypothesize that the hypercoagulable state related to COVID-19 exacerbated the underlying hereditary thrombophilia due to MTHFR-gene mutation.

Various neurological symptoms have been reported as the side effect of COVID-19 vaccines. Vaccine-associated acute Cerebellitis is very uncommon. Here, we report a 45-year-old female with acute onset cerebellitis, beginning 10 days after administration of Sinopharm vaccine. Her CSF COVID-19 PCR was found to be positive, with no pulmonary symptoms.

Background: Recombinant tissue plasminogen activator (rTPA) is the gold standard therapy for ischemic stroke patients within the appropriate time interval. In addition to its undoubtedly benefits, recognizing its possible adverse effects is of utmost importance. This study aims to investigate the possible correlation between rTPA administration and the risk of post-stroke epilepsy. Methods: In a retrospective cohort study, we enrolled subjects identified to have an ischemic stroke event without prior history of epilepsy based on their medical records. Then, followed them retrospectively regarding any subsequent seizure or epilepsy syndromes. Results: rTPA therapy showed no correlations with seizures during the first week after stroke or with the epilepsy syndromes. Positive history of prior ischemic stroke, cortical localization of stroke, cardio embolic source of the stroke, and positive hemorrhagic complication were predictors of post-stroke seizure during the first week following the stroke event. Higher final Modified Rankin Scale (MRS) and cortical localization of stroke were predictors of post-stroke epilepsy (PSE). Conclusion rTPA is a safe therapeutic measure for patients with ischemic stroke with no concerns of subsequent development of post-stroke seizure or epilepsy.

sputum acid-fast bacilli were positive and anti-TB treatment was started. Her cerebrospinal fluid results were normal except for a positive nested polymerase chain reaction (PCR) for tuberculous. She responded to protocol for treatment of status epilepticus and anti-TBM treatment and her level of consciousness improved and she became fully aware